British Journal of Dermatology · 2009 · 61 citations · 14 references
MedicineDermatologyPharmacotherapyClinical PharmacologyImmunopharmacotherapyRheumatologyAnti-inflammatory PharmacologyInflammatory Disease PharmacotherapySystemic Lupus ErythematosusTopical PreparationsDermatologic Adverse EventsDiscoid Lupus Erythematosus AlopeciaMedication-induced ErythemaPlacebo ComparatorsPlacebo-controlled Efficacy AssessmentTopical Dermatologic Therapy
BACKGROUND: In a recent open pilot trial, R-salbutamol sulphate, a well-known molecule with anti-inflammatory effects, was tested successfully on patients with therapy-resistant discoid lupus erythematosus (DLE). OBJECTIVES: To compare the efficacy and safety of R-salbutamol cream 0.5% vs. placebo on DLE lesions in a multicentre, double-blinded, randomized, placebo-controlled phase II trial. METHODS: Thirty-seven patients with at least one newly developed DLE lesion were randomized - 19 to the R-salbutamol cream 0.5% and 18 to placebo - and treated twice daily for 8 weeks. Efficacy was evaluated through scores of erythema, scaling/hypertrophy and induration as well as pain and itching; general improvement scored by the investigator and global improvement scored by patients' assessment were also evaluated. RESULTS: The mean area under the curve of improvement for scaling/hypertrophy, pain, itching and global patient assessment was significantly better for the actively treated patients as compared with placebo (scaling/hypertrophy, P = 0.0262; pain, P = 0.0238; itching, P = 0.0135; global patient assessment, P = 0.045). Moreover, the percentage of patients without induration was significantly higher in the active group compared with the placebo group (P = 0.013), and a statistically significantly greater decrease in the size of the lesional area was also seen in the overall analysis of the R-salbutamol-treated patients (P = 0.0197). No serious adverse events were reported. CONCLUSIONS: Application of R-salbutamol cream 0.5% was safe and well tolerated. Statistically significant effects were seen on scaling/hypertrophy, induration, pain and itching as well as patient global assessment, suggesting that R-salbutamol could be a promising new topical therapy alternative for DLE.
14
Cutaneous Manifestations of Rheumatic Diseases.
Alan N. Baer · Annals of the Rheumatic Diseases · 1997 · 136 citations · Full text
D BARAMKI, Jeffrey F. Koester, Andrea J. Anderson et al. · Journal of Allergy and Clinical Immunology · 2002 · 87 citations · Full text
Elisabeth Holm, Hans Christian Wulf, Lars Thomassen et al. · Journal of the American Academy of Dermatology · 2006 · 86 citations
Medicine, Dermatology, Immunology +17